Spots Global Cancer Trial Database for lymphoma, small lymphocytic
Every month we try and update this database with for lymphoma, small lymphocytic cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT00143065 | Lymphoma, Small... Lymphocytic Leu... | Fludarabine Rituximab Alemtuzumab | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Intermittent Fasting and CLL/SLL | NCT04626843 | Neoplasms Leukemia, Lymph... Lymphoma, Small... Intermittent Fa... Diet Habit Inflammation | Intermittent fa... | 19 Years - 85 Years | British Columbia Cancer Agency | |
| A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia | NCT02733042 | Lymphoma Leukemia, Lymph... | Durvalumab Lenalidomide Rituximab Ibrutinib Bendamustine | 18 Years - | Celgene | |
| Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL | NCT04342117 | Lymphoma, Small... Lymphoma Lymphoma, Non-H... Chronic Lymphoc... Follicular Lymp... | duvelisib PI3K inhibitor | 18 Years - | SecuraBio | |
| Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers | NCT02991638 | Chronic Lymphoc... Indolent B-cell... Chronic Hepatit... Lymphoma, Small... Mantle-Cell Lym... Waldenstrom's M... Follicular Lymp... | Ibrutinib | 18 Years - | The University of Hong Kong | |
| Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers | NCT02991638 | Chronic Lymphoc... Indolent B-cell... Chronic Hepatit... Lymphoma, Small... Mantle-Cell Lym... Waldenstrom's M... Follicular Lymp... | Ibrutinib | 18 Years - | The University of Hong Kong | |
| Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL) | NCT00290407 | Leukemia, Lymph... Lymphoma, Small... | Rituximab Beta-Glucan | 18 Years - | University of Louisville | |
| Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT00143065 | Lymphoma, Small... Lymphocytic Leu... | Fludarabine Rituximab Alemtuzumab | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma | NCT00060684 | Lymphoma, Low-G... Lymphoma, Small... Lymphoma, Mixed... Lymphoma, Small... | Pixantrone (BBR... fludarabine dexamethasone rituximab | 18 Years - | CTI BioPharma | |
| Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL | NCT00546793 | NHL Lymphoma, Non-H... Lymphoma, B-Cel... Lymphoma, Folli... Lymphoma, Inter... Lymphoma, Large... Lymphoma, Low-G... Lymphoma, Mixed... Lymphoma, Small... Leukemia, Lymph... Leukemia, B-Cel... Leukemia, Proly... Leukemia, Small... Lymphoma, Small... Lymphoma, Lymph... Lymphoplasmacyt... CLL SLL | veltuzumab | 18 Years - | Gilead Sciences | |
| A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL) | NCT01005979 | Leukemia, Lymph... Chronic Lymphoc... Lymphoma, Small... | Lenalidomide, R... | 18 Years - | Emory University | |
| Long-term Follow-up Study of Patients Receiving CAR-T Cells | NCT03375619 | Chronic Lymphoc... Lymphomas Non-H... Lymphoma, Small... Mantle Cell Lym... Central Nervous... Diffuse Large B... Follicular Lymp... Burkitt Lymphom... Multiple Myelom... | Long-Term Follo... | 18 Years - 80 Years | Medical College of Wisconsin | |
| Tandem Auto-Allo Transplant for Lymphoma | NCT01181271 | Diffuse, Large ... Lymphoma, Low-G... T-Cell Lymphoma Mantle-Cell Lym... Hodgkin's Lymph... Chronic Lymphoc... Lymphoma, Small... | Busulfan (condi... Etoposide (cond... Cyclophosphamid... Mesna (prior to... autologous (aut... Neupogen Fludarabine (co... Busulfan (condi... non-myeloablati... Tacrolimus Sirolimus Methotrexate | 18 Years - 75 Years | Massachusetts General Hospital | |
| A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma | NCT00081809 | Lymphoma, Folli... Lymphoma, Small... | autologous huma... | - | Agenus Inc. | |
| A Pilot Study of Pivanex in Patients With Chronic Lymphocytic Leukemia | NCT00083473 | Leukemia, Lymph... Lymphoma, Small... | Pivanex | 18 Years - | Titan Pharmaceuticals | |
| Intermittent Fasting and CLL/SLL | NCT04626843 | Neoplasms Leukemia, Lymph... Lymphoma, Small... Intermittent Fa... Diet Habit Inflammation | Intermittent fa... | 19 Years - 85 Years | British Columbia Cancer Agency | |
| A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010) | NCT05947851 | Leukemia, Lymph... Leukemia, Chron... Small-Cell Lymp... Lymphoma, Small... CLL SLL | Nemtabrutinib Venetoclax Rituximab | 18 Years - | Merck Sharp & Dohme LLC | |
| Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) | NCT03331198 | Leukemia, Lymph... Lymphoma, Small... | JCAR017 (lisoca... JCAR017 (lisoca... JCAR017 (lisoca... | 18 Years - | Juno Therapeutics, a Subsidiary of Celgene |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
